Optimizing Therapy for Lower-Risk MDS

Gary J. Schiller, MD, a hematologist/oncologist, discusses the current treatment landscape for patients with lower-risk myelodysplastic syndrome [MDS].

Expert perspectives on 2 abstracts presented at ASH 2023 looking at durable continuous transfusion independence and efficacy across different risk subgroups in the IMerge phase 3 trial in MDS.

An expert on myelodysplastic syndrome discusses the impact of mutational status on response in the IMerge phase 3 study.

Gary J. Schiller, MD, reviews recent data on durable transfusion independence for patients with lower-risk MDS in the IMerge phase 3 study and discusses how transfusion frequency affects patient outcomes.

Dr Schiller reviews data updates from the IMerge phase 3 trial looking at patient-reported outcomes and cytopenias in patients with MDS following imetelstat treatment.

An expert on MDS reviews the biomarker analysis and patient-reported outcomes from the COMMANDS study as well as long-term outcomes from the MEDALIST study.

A hematologist/oncologist discusses a phase 1b/2 study investigating canakinumab in patients with myelodysplastic syndrome.

Gary J. Schiller, MD, concludes with thoughts on the clinical implications of recent data presented at ASH 2023 on the myelodysplastic syndrome treatment landscape.